Cowen and Company’s Psyence Biomedical PBM Stock Holding History

Cowen and Company’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7	Closed	-$28.5K	–	713
2024 Q1	$28.5K	Buy	+7	New	+$29.2K	﹤0.01%	404

Other funds holding PBM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Headlands Technologies Chicago, Illinois $878M AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cowen and Company's PBM Position: Q2 2024 in Review

Cowen and Company sold out of Psyence Biomedical (PBM) in Q2 2024, closing a stake of 7 shares — an estimated $28.5K sold.

Cowen and Company first reported a position in PBM in Q1 2024 and held it in 1 quarter. The position peaked at $28.5K in Q1 2024. 8 funds tracked by Wall St. Rank hold PBM as of Q2 2024.

Cowen and Company reported no remaining Psyence Biomedical position as of Q2 2024 after selling out during the quarter.
Cowen and Company sold 7 Psyence Biomedical shares in Q2 2024, an estimated $28.5K.
Cowen and Company first reported a position in Psyence Biomedical in Q1 2024 and held it in 1 quarter.
Cowen and Company's Psyence Biomedical position peaked at $28.5K in Q1 2024.
8 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2024.

Based on Cowen and Company's 13F filing for Q2 2024, filed 7 Aug 2024.